A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC).

Reviewer: Walter Sall, MD
OncoLink
Ultima Vez Modificado: 15 de mayo del 2005

Translation for this article does not exist